Bristol Myers Squibb Reports Five-Year Camzyos Data
PRINCETON, N.J., August 26, 2026 Bristol Myers Squibb presented new long-term data for Camzyos® (mavacamten) at the European Society...
mavacamten
Advertisement
Bristol Myers Camzyos Shows Strong Results in HCM Trial
PRINCETON, N.J., USA, March 29, 2026 Bristol Myers Squibb has announced positive Phase 3 results from the SCOUT-HCM trial...
Bristol Myers Squibb Reports New Camzyos Data at ACC
PRINCETON, NEW JERSEY, March 23, 2026 Bristol Myers Squibb has unveiled new clinical and real-world data for Camzyos (mavacamten)...
Bristol Myers Squibb Unveils New Long-Term and Real-World Data for Camzyos at AHA 2025
Princeton, N.J., November 4, 2025 – Bristol Myers Squibb (NYSE: BMY) announced a major scientific milestone with the presentation...
Advertisement
